LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

Search

BioCryst Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

7.62 -0.13

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

7.55

Massimo

7.62

Metriche Chiave

By Trading Economics

Entrata

5.1M

5.1M

Vendite

18M

163M

Margine di Profitto

3.113

Dipendenti

580

EBITDA

7.2M

28M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+129.36% upside

Dividendi

By Dow Jones

Utili prossimi

3 nov 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-172M

1.7B

Apertura precedente

7.75

Chiusura precedente

7.62

Notizie sul Sentiment di mercato

By Acuity

50%

50%

132 / 371 Classifica in Healthcare

BioCryst Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

26 set 2025, 18:25 UTC

I principali Market Mover

Mirion Technologies Stock Rises on Expanded Notes, Shares Offerings

27 set 2025, 07:00 UTC

Utili

This Water Stock Is Dehydrated. What Could Bring It Back. -- Barrons.com

27 set 2025, 04:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

26 set 2025, 21:56 UTC

Acquisizioni, Fusioni, Takeovers

Staar Surgical, Insight Enterprises, and More Stocks See Action From Activist Investors -- Barrons.com

26 set 2025, 20:54 UTC

Utili

U.S. TikTok for $14 Billion? Making Sense of the Bargain-Basement Price. -- Barrons.com

26 set 2025, 20:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

26 set 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

26 set 2025, 20:27 UTC

Acquisizioni, Fusioni, Takeovers

Electronic Arts Stock Pops on Report Videogame Maker Is Close to Going Private -- Barrons.com

26 set 2025, 20:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

26 set 2025, 19:54 UTC

Discorsi di Mercato

Canada's Can't-Build Reputation Is Somewhat Earned -- Market Talk

26 set 2025, 19:53 UTC

Acquisizioni, Fusioni, Takeovers

Electronic Arts Stock Pops on Report Videogame Maker Is Close to Going Private -- Barrons.com

26 set 2025, 19:40 UTC

Utili

The U.S. TikTok Is Apparently Fetching a Bargain-Basement Price. A Few Reasons Why. -- Barrons.com

26 set 2025, 19:24 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Mixed As October Expires -- Market Talk

26 set 2025, 19:17 UTC

Discorsi di Mercato

Oil Posts Weekly Gains on Russia-Ukraine Tensions -- Market Talk

26 set 2025, 19:15 UTC

Discorsi di Mercato

AI Deployment Beginning to Weigh on Job Creation, Former Central Banker Says -- Market Talk

26 set 2025, 19:03 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

26 set 2025, 19:03 UTC

Discorsi di Mercato

Gold Fuels Stellar Performance in Toronto Stock Market -- Market Talk

26 set 2025, 18:50 UTC

Discorsi di Mercato
Utili

Costco's Executive Membership Gains Seen as Offsetting Slower Renewal Rates -- Market Talk

26 set 2025, 18:36 UTC

Discorsi di Mercato

Silver Closes Out Week With Strong Surge -- Market Talk

26 set 2025, 18:02 UTC

Acquisizioni, Fusioni, Takeovers

ING: Continue Working Towards Completing Transaction, Exit From Russian Market >ING

26 set 2025, 18:02 UTC

Acquisizioni, Fusioni, Takeovers

ING: Global Development Hasn't Received All Necessary Approvals >ING

26 set 2025, 18:02 UTC

Acquisizioni, Fusioni, Takeovers

ING: No Realistic Prospect of Completing Sale of ING Bank (Eurasia) to Global Development in 3Q

26 set 2025, 17:54 UTC

Discorsi di Mercato

U.S. Oil Rig Count Rises For Fifth Straight Week -- Market Talk

26 set 2025, 16:56 UTC

Discorsi di Mercato
Utili

Costco Increasingly Challenged to Meet Lofty Expectations -- Market Talk

26 set 2025, 16:41 UTC

Discorsi di Mercato
Utili

Costco's Valuation Seen as Too High Amid Slow Down -- Market Talk

26 set 2025, 16:26 UTC

Utili

Correction to Sherwin-Williams Extends Losses. What's Ailing the Paint Maker. -- Barrons.com

26 set 2025, 16:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

26 set 2025, 16:12 UTC

Discorsi di Mercato

Nike Stock Seen With Limited Upside -- Market Talk

26 set 2025, 15:59 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

26 set 2025, 15:59 UTC

Discorsi di Mercato

Nike Seen Showing Progress in Turnaround -- Market Talk

Confronto tra pari

Modifica del prezzo

BioCryst Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

129.36% in crescita

Previsioni per 12 mesi

Media 17.5 USD  129.36%

Alto 30 USD

Basso 12 USD

Basato su 6 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per BioCryst Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

6 ratings

6

Acquista

0

Mantieni

0

Vendi

Sentiment

By Acuity

132 / 371 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
help-icon Live chat